Cannabinoids as Drugs – Latest Updates

In this webinar, we will discuss the current status of cannabinoids as medical products in the United States. The focus will be on what we can learn from the FDA approval of Epidolex (Cannabidiol) oral solution 100 mg/mL. We will also talk about the ways to obtain research information. The current market for Cannabidiol (CBD) in the United States will be discussed. This information may be useful in predicting the future of cannabinoids in the United States. The legality of foods containing CBD will be considered.

Why You Should Attend:

This training will provide valuable information to those who are deciding which products to pursue and those who develop them or submit their applications. The status of Cannabinoids in the United States is changing rapidly. This webinar will attempt to discuss the latest FDA updates and market information about them.

Areas Covered in the Session :

• What are Cannabinoids
• Legal Status of Cannabinoids
• How was Epidolex approved
• The current marketing of CBD
• Research on Cannabinoids
• Possible future Cannabinoids

Who Should Attend:

• Pharmaceutical Executives
• Pharmaceutical Research and Development
• Pharmaceutical Regulatory Affairs
• Food Research and Development
• Food Executives
• Quality Professionals
• Regulatory Compliance Officers

Course Director: DR. LOREN GELBER

Dr. Loren Gelber has more than 40 years of experience in pharmaceutical industry regulatory compliance. She worked for about 10 years at the FDA, including as a reviewer in the Division of Generic Drugs. She then transitioned to industry, working for four different pharmaceutical companies. For the last 13 years she has been a regulatory compliance consultant, both for consulting companies and independently.